Lexaria Bioscience Secures $3.5M in Capital to Fuel Drug Delivery Innovation

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, has successfully closed a significant capital raise, securing approximately $3.5 million in gross proceeds. The company executed a registered direct offering of 2,661,600 shares of common stock at $1.315 per share, priced at-the-market under Nasdaq rules. In a concurrent private placement, Lexaria also issued unregistered warrants to purchase an equal number of shares, exercisable at $1.19 per share and expiring five years from the effectiveness of a resale registration statement. H.C. Wainwright & Co. acted as the exclusive placement agent for this strategic financial move. The company intends to allocate the net proceeds to advance its research and development initiatives, fund working capital, and support other general corporate purposes, signaling a strong commitment to growth and innovation.

The offering was conducted under a "shelf" registration statement (Form S-3, File No. 333-284407) declared effective by the Securities and Exchange Commission (SEC) on January 30, 2025. Detailed information about the offering is available through the SEC's website at www.sec.gov, where investors can access the prospectus supplement and accompanying prospectus. The warrants and underlying shares from the private placement were issued under exemptions from registration, meaning they cannot be offered or sold in the United States without an effective registration statement or applicable exemption. This financial maneuver underscores Lexaria's proactive approach to funding its operations while navigating complex regulatory frameworks to ensure compliance and transparency for stakeholders.

At the core of Lexaria's mission is its patented DehydraTECH™ drug delivery platform, which enhances oral drug absorption, reduces side-effects, and improves delivery across the blood-brain barrier. With 56 patents granted and more pending worldwide, the company operates a licensed in-house research laboratory, positioning itself as a leader in pharmaceutical innovation. For more information, visit www.lexariabioscience.com. This capital infusion is poised to accelerate Lexaria's R&D efforts, potentially leading to breakthroughs in drug delivery that could transform patient care. The news was originally released on www.newmediawire.com, highlighting the company's ongoing efforts to communicate its progress and strategic initiatives to the investment community and beyond.